Dr Reddy’s Laboratories has launched over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7 percent, the generic equivalent of Extra Strength Pataday Once-Daily Relief, in the US market, as approved by the US Food and Drug Administration (FDA).

Dr Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7 percent is an Antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander.

“This launch adds to our current portfolio in the OTC eye-care space which includes Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2 percent and 0.1 percent strengths. The first-to-market launch is a testament to our deep capabilities in bringing store-brand equivalents of OTC brands in the U.S. market. We are excited to deepen our collaboration with our retail customers through this important addition to our store-brand portfolio,” explained Milan Kalawadia, CEO, North America Generics, Dr Reddy’s Laboratories,

The Pataday brand had US sales of approximately USD 69.9 million for the latest 52 weeks period ending 27 December, 2025, according to NIQ data.

Dr Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7 percent is available in a 2.5 mL bottle.